Pharmaceutical CXO Companies Strategic Expansion

Pharmaceutical CXO Market Top Companies and Their Offerings

What are the Recent Developments in the Pharmaceutical CXO Market?

• In April 2026, a series of major infrastructure investments was announced by PCI Pharma Services, which is a contract development and manufacturing organization (CDMO) focused on innovative small molecule therapies and biologics. This investment will strengthen its sterile fill-finish capabilities and drug delivery capabilities, as well as support drug product development, manufacturing, and clinical trials.
• In September 2025, the launch of in-house formulation development services was announced by Cytovance Biologics, which is a U.S.-based Contract Development and Manufacturing Organization (CDMO). This expansion will strengthen its position as a full-service partner for biologic drug developers, where it will offer services to biotech and pharmaceutical clients.

Pharmaceutical CXO Market Value Chain Analysis

R&D

• The R&D of the pharmaceutical CXO focuses on offering early-stage drug discovery, advanced biologic drug development, and clinical trial data analytics services.
• Key players: IQVIA, Charles River Laboratories, and Lonza Group.

Clinical Trials and Regulatory Approvals

• Management of phase I-VI, decentralized trials, and regulatory compliance are the services offered by a pharmaceutical CXO during clinical trials and regulatory approvals.
• Key players: IQVIA, ICON plc, Medpace.

Patient Support and Services

• Specialized nurse-led hub network, clinical home health visits, and digital patient engagement portals are also provided in the patient support and services of the pharmaceutical CXO.
• Key players: IQVIA, ICON plc.

Market Growth

The global pharmaceutical CXO market size was estimated at USD 382.6 billion in 2025 and is predicted to increase from USD 416.65 billion in 2026 to approximately USD 897.48 billion by 2035, expanding at a CAGR of 8.9% from 2026 to 2035.